Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.

Original languageEnglish
Pages (from-to)123-126
Number of pages4
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume74
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

Fingerprint

Interleukin-4
Interferons
Multiple Sclerosis
T-Lymphocytes
Therapeutics
Th2 Cells
Lymphopenia
Methylprednisolone
T-Lymphocyte Subsets
Therapeutic Uses
Innate Immunity
Cellular Immunity
Glucocorticoids
Flow Cytometry
Cytokines
Glatiramer Acetate
Interferon beta-1a

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

@article{8f9c06ceb6c14229b4e9149e8b1968b1,
title = "Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment",
abstract = "Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.",
author = "Diego Franciotta and E. Zardini and R. Bergamaschi and L. Andreoni and V. Cosi",
year = "2003",
month = "1",
day = "1",
doi = "10.1136/jnnp.74.1.123",
language = "English",
volume = "74",
pages = "123--126",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment

AU - Franciotta, Diego

AU - Zardini, E.

AU - Bergamaschi, R.

AU - Andreoni, L.

AU - Cosi, V.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.

AB - Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.

UR - http://www.scopus.com/inward/record.url?scp=0037228948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037228948&partnerID=8YFLogxK

U2 - 10.1136/jnnp.74.1.123

DO - 10.1136/jnnp.74.1.123

M3 - Article

C2 - 12486283

AN - SCOPUS:0037228948

VL - 74

SP - 123

EP - 126

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

ER -